Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Zamosc – page 4

93 clinical trials in Zamosc, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Zamosc at a glance
93
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

93 trials in Zamosc

Open in trial search

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Human metapneumovirus, virus-like protein
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Mabxience Research S.L.

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Colitis ulcerative

Not yet recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Gastrooesophageal reflux disease+1

Not recruiting

Study of linaprazan glurate and lansoprazole to maintain healing in patients with erosive esophagitis caused by acid reflux disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lansoprazole
  • Sponsor:Cinclus Pharma Holding AB (publ)

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Cardiovascular disorder

Not recruiting

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Migraine

Not recruiting

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Therapeutics GmbH

Migraine

Not recruiting

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Therapeutics GmbH

Gastrooesophageal reflux disease+1

Not recruiting

Comparison of linaprazan glurate versus lansoprazole for healing of erosive esophagitis in adults with gastroesophageal reflux disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lansoprazole
  • Sponsor:Cinclus Pharma Holding AB (publ)

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Zamosc

What the registry says about research in the country

01 Respiratory Research

Innovative trials focusing on respiratory infections and prevention strategies, including studies of vaccines against RSV and influenza in older adults.

  • Respiratory Syncytial Virus (RSV)
  • Human Metapneumovirus (hMPV)
  • Influenza Prevention

These studies aim to enhance protection against common respiratory illnesses in vulnerable populations.

02 Gastrointestinal Studies

Comprehensive research into inflammatory bowel conditions, with multiple trials examining new treatments for Crohn's Disease and Ulcerative Colitis.

  • Moderate to Severe Ulcerative Colitis
  • Fibrostenotic Crohn's Disease
  • Novel Therapeutic Approaches

Investigations focus on both established and experimental treatments to improve disease management.

03 Cardiovascular Research

Advanced studies targeting atherosclerotic cardiovascular disease and stroke prevention in patients with atrial fibrillation.

  • Stroke Prevention
  • Atherosclerosis Management
  • Cardiovascular Risk Reduction

Trials evaluate innovative treatments to reduce major adverse cardiovascular events.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.